• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    5/14/24 4:31:13 PM ET
    $AKLI
    $ARQT
    $BBLG
    $BCAB
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKLI alert in real time by email

    Gainers

    • Arcutis Biotherapeutics (NASDAQ:ARQT) stock moved upwards by 16.4% to $9.46 during Tuesday's after-market session. The company's market cap stands at $1.0 billion. As per the press release, Q1 earnings came out today.
    • BioAtla (NASDAQ:BCAB) stock rose 13.02% to $2.95. The market value of their outstanding shares is at $141.9 million. As per the news, the Q1 earnings report came out today.
    • OptimizeRx (NASDAQ:OPRX) stock increased by 7.55% to $11.25. The company's market cap stands at $204.5 million. As per the news, the Q1 earnings report came out today.
    • Psyence Biomedical (NASDAQ:PBM) stock moved upwards by 6.74% to $0.93. The market value of their outstanding shares is at $12.4 million.
    • Bone Biologics (NASDAQ:BBLG) shares rose 6.08% to $2.44. The market value of their outstanding shares is at $2.1 million.
    • SINTX Techs (NASDAQ:SINT) stock rose 5.81% to $0.06. The market value of their outstanding shares is at $7.1 million. As per the press release, Q1 earnings came out yesterday.

    Losers

    • Bolt Biotherapeutics (NASDAQ:BOLT) stock fell 15.9% to $1.11 during Tuesday's after-market session. The market value of their outstanding shares is at $42.3 million.
    • Vivos Therapeutics (NASDAQ:VVOS) stock declined by 12.86% to $2.17. The company's market cap stands at $6.4 million. The company's, Q1 earnings came out today.
    • Iridex (NASDAQ:IRIX) shares decreased by 12.0% to $2.71. The company's market cap stands at $44.0 million. As per the press release, Q1 earnings came out today.
    • Prestige Consumer (NYSE:PBH) stock fell 7.66% to $66.0. The market value of their outstanding shares is at $3.2 billion. As per the press release, Q4 earnings came out today.
    • Akili (NASDAQ:AKLI) shares decreased by 7.32% to $0.41. The market value of their outstanding shares is at $32.4 million. As per the news, the Q1 earnings report came out today.
    • Ocean Biomedical (NASDAQ:OCEA) shares fell 5.77% to $1.47. The market value of their outstanding shares is at $50.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKLI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKLI
    $ARQT
    $BBLG
    $BCAB

    CompanyDatePrice TargetRatingAnalyst
    BioAtla Inc.
    $BCAB
    1/13/2026$4.00Buy
    Rodman & Renshaw
    Bolt Biotherapeutics Inc.
    $BOLT
    10/20/2025$7.00Buy
    H.C. Wainwright
    Prestige Consumer Healthcare Inc.
    $PBH
    9/24/2025$80.00Neutral → Buy
    Sidoti
    BioAtla Inc.
    $BCAB
    8/13/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    Arcutis Biotherapeutics Inc.
    $ARQT
    7/25/2025$18.00Neutral
    Goldman
    OptimizeRx Corporation
    $OPRX
    1/8/2025$7.00 → $6.00Outperform → Sector Perform
    RBC Capital Mkts
    Arcutis Biotherapeutics Inc.
    $ARQT
    12/30/2024$19.00Buy
    H.C. Wainwright
    OptimizeRx Corporation
    $OPRX
    12/20/2024$5.50Equal-Weight
    Stephens
    More analyst ratings

    $AKLI
    $ARQT
    $BBLG
    $BCAB
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Prestige Consumer Healthcare Inc.

    SCHEDULE 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

    3/27/26 11:21:10 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by OptimizeRx Corporation

    SCHEDULE 13G/A - OptimizeRx Corp (0001448431) (Subject)

    3/27/26 11:05:06 AM ET
    $OPRX
    Real Estate

    IRIDEX Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - IRIDEX CORP (0001006045) (Filer)

    3/26/26 4:22:19 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AKLI
    $ARQT
    $BBLG
    $BCAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Iridex Reports Fourth Quarter and Full Year 2025 Financial Results

    MOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 Financial Highlights Generated total revenue of $14.7 million, representing growth of 16% year-over-year compared to $12.7 million in the prior year quarterCyclo G6® product family revenue was $3.8 million, representing growth of 15% year-over-year compared to $3.3 million in the prior year quarter Sold 15,900 Cycl

    3/26/26 4:05:00 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market

    Insurance Coverage on Vivos Appliances and Treatment Now Available to a Significant Number of Nevada Patients Previously Unable to Access Coverage Concurrently, Vivos Implements Cost Reduction Initiatives Related to Legacy Business Model to Focus on Scaling its Medical Affiliation Distribution Model LITTLETON, Colo., March 26, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (OSA), today announced that physician-owned professional entities supported by t

    3/26/26 8:45:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

    Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026 SALT LAKE CITY, Utah, March 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today provided a corporate business update highlighting recent clinical, operational, and leadership milestones that the Company believes position it for commercial expansion and future revenue growth. The update follows a series of key developments, including the successful completion of the first human surgical procedure us

    3/23/26 9:15:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $AKLI
    $ARQT
    $BBLG
    $BCAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Dizon Romeo R bought $1,399 worth of shares (1,110 units at $1.26), increasing direct ownership by 0.93% to 121,000 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    3/9/26 1:05:37 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $AKLI
    $ARQT
    $BBLG
    $BCAB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form

    12/19/23 3:40:08 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    12/15/23 5:01:31 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKLI
    $ARQT
    $BBLG
    $BCAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by SiNtx Technologies Inc.

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/18/26 9:02:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Chief Medical Officer Sievers Eric was granted 240,000 shares, increasing direct ownership by 67% to 598,705 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    3/12/26 4:08:15 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Short Jay M Phd was granted 430,000 shares, increasing direct ownership by 19% to 2,659,603 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    3/12/26 4:07:56 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKLI
    $ARQT
    $BBLG
    $BCAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on BioAtla with a new price target

    Rodman & Renshaw initiated coverage of BioAtla with a rating of Buy and set a new price target of $4.00

    1/13/26 3:22:40 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright resumed coverage on Bolt Biotherapeutics with a new price target

    H.C. Wainwright resumed coverage of Bolt Biotherapeutics with a rating of Buy and set a new price target of $7.00

    10/20/25 8:44:35 AM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer upgraded by Sidoti with a new price target

    Sidoti upgraded Prestige Consumer from Neutral to Buy and set a new price target of $80.00

    9/24/25 7:53:30 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKLI
    $ARQT
    $BBLG
    $BCAB
    Leadership Updates

    Live Leadership Updates

    View All

    SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

    Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026 SALT LAKE CITY, Utah, March 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today provided a corporate business update highlighting recent clinical, operational, and leadership milestones that the Company believes position it for commercial expansion and future revenue growth. The update follows a series of key developments, including the successful completion of the first human surgical procedure us

    3/23/26 9:15:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") today reinforced how its strategic investment in PsyLabs strengthens its control over pharmaceutical-grade manufacturing and commercial supply chain infrastructure – a critical differentiator in the rapidly expanding psychedelic pharmaceutical sector. Through its investment in PsyLabs, Psyence BioMed has secured: A licensed, owned, and debt-free production operation.Source-level ibogaine supply.Natural psilocybin supply.GMP-compliant manufacturing capabilities.Intellectual property protection.Integrated analytical and chemistry laboratory infrastructure.A capital structur

    3/11/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

    Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX Technologies, Inc., effective March 16, 2026. Mr. Elmore most recently served as Core Business Director at Invibio, a division of Victrex plc. With more than 15 years of experience in advanced biomaterials and medical dev

    2/18/26 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $AKLI
    $ARQT
    $BBLG
    $BCAB
    Financials

    Live finance-specific insights

    View All

    Iridex Reports Fourth Quarter and Full Year 2025 Financial Results

    MOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 Financial Highlights Generated total revenue of $14.7 million, representing growth of 16% year-over-year compared to $12.7 million in the prior year quarterCyclo G6® product family revenue was $3.8 million, representing growth of 15% year-over-year compared to $3.3 million in the prior year quarter Sold 15,900 Cycl

    3/26/26 4:05:00 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Prestige Consumer Healthcare Announces Agreement to Acquire Breathe Right®, the Leader in Nasal Strips

    Entered agreement to acquire a portfolio of brands with revenue of $200 million and EBITDA of $95 millionBreathe Right is an iconic and category‑leading brand with strong margins and cash flow generationAcquisition reinforces Prestige's long-term organic growth algorithmTransaction expected to close in Prestige's first half fiscal 2027 TARRYTOWN, N.Y., March 20, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (the "Company" or "Prestige") (NYSE:PBH) today announced that it has entered into a definitive agreement to acquire the Breathe Right® brand and certain other brands from Foundation Consumer Healthcare for $1.045 billion, or approximately $900 million net of anticipated ta

    3/20/26 6:15:00 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026

    MOUNTAIN VIEW, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the fourth quarter and full year 2025 and provide a business update after the close of trading on March 26, 2026. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-646-307-1963 from the US or +1-800-715-9871 internationally and pro

    3/12/26 4:05:00 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AKLI
    $ARQT
    $BBLG
    $BCAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Psyence Biomedical Ltd.

    SC 13G - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/13/24 9:16:01 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/9/24 1:36:43 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

    SC 13G/A - OptimizeRx Corp (0001448431) (Subject)

    12/6/24 4:26:03 PM ET
    $OPRX
    Real Estate